Source comparison
PT-141 Safety Profile: Duration-Based Comparison
Weeks 1–8 (Acute Phase) Nausea, flushing, transient BP elevation, headache 40–60% experience at least one Pre-treatment BP, injection technique education Complete resolution within 48–72 hours Weeks 8–24 (Intermediate) Mild hyperpigmentation (sun-exposed areas
This comparison does not assign a generated winner or score.
- Weeks 1–8 (Acute Phase)
- Nausea, flushing, transient BP elevation, headache
- 40–60% experience at least one
- Pre-treatment BP, injection technique education
- Complete resolution within 48–72 hours
- Weeks 8–24 (Intermediate)
- Mild hyperpigmentation (sun-exposed areas), intermittent nausea (decreasing), injection site reactions
- 15–25% hyperpigmentation, 10–15% persistent nausea
- BP check every 4 weeks, dermatologic self-monitoring
- Pigmentation fades over 3–6 months post-cessation
- Beyond 24 Weeks (Chronic)
- Sustained baseline BP elevation, non-dipping nocturnal BP pattern, progressive hyperpigmentation, rare RPE changes
- 12% cardiovascular, 8–14% dermatologic, <1% ophthalmologic
- 24-hour ABPM at months 6 and 12, annual dilated fundus exam, monthly BP tracking
- BP normalises within 4–8 weeks; pigmentation resolves slowly over 6–12 months; RPE reversibility unknown